OBJECTIVE Placebo response in studies of binge eating disorder (BED) has raised concern about its diagnostic stability. The aims of this study were (1) to compare placebo responders (PRs) with nonresponders (NRs); (2) to investigate the course of BED following placebo response; and (3) to examine attributions regarding placebo response. METHOD The baseline placebo run-in phase (BL) was part o...

BACKGROUND Obesity causes serious medical complications and impairs quality of life. However, its management remains challenging. OBJECTIVE To assist health professionals who counsel patients who are overweight or obese by discussing the possible add-on value of new drugs over lifestyle interventions. METHODS A critical analysis is made of the available evidence of the long-term efficacy of...

INTRODUCTION Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. AREAS COVERED The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy a...

BACKGROUND Antipsychotic-induced metabolic adversities are often difficult to manage. Using concomitant medications to counteract these adversities may be a rational option. OBJECTIVE To systematically determine the effectiveness of medications to counteract antipsychotic-induced metabolic adversities in patients with schizophrenia. DATA SOURCES Published articles until November 2013 were s...

We established depressive symptoms prevalence in 100 patients recommended to our obesity clinic and we started antidepressant treatment in 41 of them. It has been noted that administration of SSRI leads to weight reduction after 6 months, but is followed by a weight increase later. Our experience shows that 12 months long administration of bupropion and tianeptine leads to continuous weight los...